Given that HER2 positive ovarian cancer patients show limited response to targeted therapies that are successful in the treatment of HER2 positive breast cancer, these findings can be utilized in developing ovarian carcinoma specific therapeutics [22–26]. Here, ERBB2 is linked to breast cancer.